RB1
protein-codingRB transcriptional corepressor 1, the group of Receptor ligands
Gene summary
The protein encoded by this gene is a negative regulator of the cell cycle and was the first tumor suppressor gene found. The encoded protein also stabilizes constitutive heterochromatin to maintain the overall chromatin structure. The active, hypophosphorylated form of the protein binds transcription factor E2F1. Defects in this gene are a cause of childhood cancer retinoblastoma (RB), bladder cancer, and osteogenic sarcoma. [provided by RefSeq, Jul 2008]
- OSRC
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~295.7 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0018160
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0005105
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0018160
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0018160
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0018160
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0008380
Submitter: ClinGen
Retinoblastoma (RB) is an embryonic malignant neoplasm of retinal origin. It almost always presents in early childhood and is often bilateral. The retinoblastoma gene (RB1) was the first tumor suppressor gene identified based on location in the region of 13q14 germline deletion in some patients with retinoblastoma (PMID: 3480530). Oncogenic point mutations in RB1 were first reported by Yandell DW, et al., 1989 (PMID: 2594029). RB1 encodes a negative regulator of the cell cycle through its ability to bind the transcription factor E2F and repress transcription of genes required for S phase (PMID: 10647931). There is abundant evidence published associating the RB1 gene with retinoblastoma. Multiple case level studies (PMID: 2594029, 25928201) and a case control study (PMID: 28193182) have been performed with retinoblastoma patients that have variants in the RB1 gene. The variants include single amino acid changes, the whole gene deletion (about 3-5%) and nonsense or frameshift LOF variants. Many de novo variants were reported. A significant amount of case-level data is available, but the maximum points for genetic evidence has been reached (12 points). A zebrafish model of RB1 has been established to show development of retinoblastoma consistent with the disease phenotype. Tumor formation was observed when the IRBP-Cre:Rb1-/- mice were crossed with Tp53 mice to heterozygosity. In summary, RB1 is definitively associated with autosomal dominant retinoblastoma. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.
Clinical Genomic Database (CGD)
Manifestation: Oncologic
Intervention: Oncologic
Rationale: Frequent and regular eye examination (including under anesthesia if necessary) starting in infancy is indicated in order to detect ocular neoplasms, which may allow early detection and treatment; Awareness of the risk of additional neoplasms may allow early detection and treatment based on signs/symptoms (eg, bone pain); Limiting exposure to DNA-damaging agents (including high-dose radiotherapy) may be beneficial
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to RB1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_000321.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 4 | 3 | 15 | 672 | 17 | 711 |
| missense | 15 | 36 | 1561 | 235 | 6 | 1853 |
| nonsense | 175 | 10 | 3 | 188 | ||
| start loss | 1 | 2 | 3 | |||
| frameshift | 439 | 41 | 19 | 499 | ||
| splice donor/acceptor (+/-2bp) | 148 | 44 | 22 | 1 | 215 | |
| Total | 781 | 135 | 1622 | 908 | 23 | 3469 |
Highest pathogenic variant AF is 0.004362775
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_000312.2 | 27 | MANE Select | |
| Ensembl | ENSP00000267163.4 | 27 | MANE Select | |
| RefSeq | NP_001394094.1 | 27 | Standard | |
| RefSeq | NP_001394095.1 | 17 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| rb1 | Danio rerio | Structure: retinal ganglion cell Quality: misrouted abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Non-small cell lung cancer - Homo sapiens (human)
- Chronic myeloid leukemia - Homo sapiens (human)
- Gastric cancer - Homo sapiens (human)
- Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human)
- Melanoma - Homo sapiens (human)
Biological Process
- G1/S transition of mitotic cell cycle
- negative regulation of transcription by RNA polymerase II
- regulation of cell growth
- tissue homeostasis
- aortic valve morphogenesis
Molecular Function
- proximal promoter sequence-specific DNA binding
- RNA polymerase II regulatory region DNA binding
- RNA polymerase II activating transcription factor binding
- DNA binding
- DNA-binding transcription factor activity
Cellular Component
- chromatin
- nucleus
- nucleoplasm
- transcription factor complex
- spindle
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000267163
- Coding exons
- 27
- Length
- 178236
- Individuals with no LoFs
- 125681
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 5
- Defined
- 125686
- p
- 0.0000199
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.67 | 311 | 475 | 0.655 | 0.0000238 | 6073 |
| Missense (PolyPhen) | 86 | 186.59 | 0.4609 | 2409 | ||
| Synonymous | 0.488 | 152 | 160 | 0.951 | 0.00000782 | 1707 |
| Loss of Function | 6.93 | 3 | 61.8 | 0.0486 | 0.00000378 | 715 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000068 | 0.000062 | rare |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000037 | 0.000035 | rare |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Key regulator of entry into cell division that acts as a tumor suppressor. Promotes G0-G1 transition when phosphorylated by CDK3/cyclin-C. Acts as a transcription repressor of E2F1 target genes. The underphosphorylated, active form of RB1 interacts with E2F1 and represses its transcription activity, leading to cell cycle arrest. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex (By similarity). In case of viral infections, interactions with SV40 large T antigen, HPV E7 protein or adenovirus E1A protein induce the disassembly of RB1-E2F1 complex thereby disrupting RB1's activity. {ECO:0000250, ECO:0000269|PubMed:15084261}.;
- Disease
- DISEASE: Childhood cancer retinoblastoma (RB) [MIM:180200]: Congenital malignant tumor that arises from the nuclear layers of the retina. It occurs in about 1:20'000 live births and represents about 2% of childhood malignancies. It is bilateral in about 30% of cases. Although most RB appear sporadically, about 20% are transmitted as an autosomal dominant trait with incomplete penetrance. The diagnosis is usually made before the age of 2 years when strabismus or a gray to yellow reflex from pupil ('cat eye') is investigated. {ECO:0000269|PubMed:10671068, ECO:0000269|PubMed:11524739, ECO:0000269|PubMed:1352883, ECO:0000269|PubMed:2594029, ECO:0000269|PubMed:7704558, ECO:0000269|PubMed:7795591, ECO:0000269|PubMed:7927327, ECO:0000269|PubMed:8346255, ECO:0000269|PubMed:8605116, ECO:0000269|PubMed:8776589, ECO:0000269|PubMed:9140452, ECO:0000269|PubMed:9311732, ECO:0000269|PubMed:9973307}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcoma originating in bone-forming cells, affecting the ends of long bones. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.970
Intolerance Scores
- LoFtool
- 0.00806
- RVIS EVS
- -0.69
- RVIS percentile EVS
- 15.12
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 1.00
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |